BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 27, 2009 at 3.15 p.m. Biotie Therapies Corp. Annual Report 2008 published Biotie Therapies Corp. Annual Report for 2008 has been published. The Annual Report can be downloaded in pdf format from the Biotie website at www.biotie.com. The printed version of the Annual Report can be ordered from the company, telephone +358 2 274 8900, e-mail virve.nurmi@biotie.com or address Tykistökatu 6, 20520 Turku, Finland. Turku April 27, 2009 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: Distribution: NASDAQ OMX Helsinki Ltd Main Media www.biotie.com Biotie Therapies Corp. Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.